HLTH:NYSE; NHC:TSX

Nobilis Health Corp.

Nobilis is a full-service healthcare development and management company which currently owns or manages four surgical hospitals and five ASCs, partners with an additional thirty-three facilities throughout the country, and markets six independent brands. Deploying a unique patient acquisition strategy driven by direct-to-consumer marketing, Nobilis is focused on a specified set of procedures that are performed at our centers by local physicians.
HLTH:NYSE NHC:TSX

Expert Comments:

Management Q&A: View From the Top
Kolin Ozonian
Managing both acquisitions and internal growth at the same time is difficult for most small companies, but not for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue.
read more >
Russell Stanley, Mackie Research Capital (5/25/16)
"We continue to view Nobilis Health Corp. as an undervalued play on growing demand for high acuity surgery in the U.S. . .our revised revenue estimate is in line with management's guidance for organic revenue growth of $275 million. . .our forecast assumes organic top-line growth of 18%, as well as modest margin improvement. . .we believe the current share price is already discounting this year's guidance. At current levels, the stock is trading at just 5x our adjusted EBITDA estimate for this year."

William Sutherland, Emerging Growth Equities Ltd. (5/23/16)
"Nobilis reported a Q1 with solid revenue growth but with a larger loss than is seasonally typical due to investment and non-recurring items. . .investors need to keep in mind the heightened seasonality of the company's out-of-network model that drives the majority of profit into the back half of the year. . .we view the shares as oversold at current levels. . .Nobilis trades at wide discounts to peers, particularly relative to growth. Achieving our $7 TP implies the company trades at 2016E EV/EBITDA of 8.5x, still a meaningful discount to slower-growing peers."

Sheila Broughton, PI Financial (5/13/16)
"Nobilis Health Corp.'s revenue increased 35% to $51.3M from $37.9M in Q115, beating consensus of $49.1M. . .Revenue per case at NHC facilities increased 15% to $12,036 from $10,475 in Q115. . .Nobilis continues to focus on higher acuity cases to increase both revenue per case and overall operating margin. . .We are maintaining our BUY rating."

Russell Stanley, Mackie Research Capital (5/3/16)
"We continue to rate Nobilis Health Corp. as a Buy with 12-month target price of CDN$12.50 per share. We view the company as an undervalued play on growing demand for high acuity surgery in the United States. . .potential catalysts include the Q1/16 results as well as additional M&A."

Shane Matte, BioTuesdays (5/2/16)
"Nobilis Health Corp. has launched a comprehensive technology platform called Concertis that will develop new payment and delivery methodologies to enhance value for patients, payers, and providers across the continuum of care. . .Concertis will negotiate with insurance companies and self-insured employers to combine reimbursement for multiple providers and facilities into a single comprehensive bundled payment that covers all of the services involved in a patient’s episode of care. This clinical integration strategy will result in improved patient outcomes, integrated care, expense savings, and enhanced revenue. . .Concertis will aggregate patient data from multiple platforms and analyze it to manage specific diseases and episodes of care—this powerful data tool will enable health care providers, facilities, and payers to improve clinical and financial outcomes through implementation of clinical best practices."

Darspal S. Mann, Seeking Alpha (4/22/16)
"The rollout of the bundled payments model, move toward the network, new partnerships, more products, etc. are some of the opportunities that should help Nobilis Health Corp. achieve the targeted 20% organic growth. . .it is not unusual for an emerging story to raise questions, but the risk/reward ratio is favorable enough to monitor the name closely."

Management Q&A: View From the Top
Kolin Ozonian
Businesses can grow in two ways—internally and externally. Nobilis Health Corp. has a voracious appetite for both. The company is a development and management firm that acquires private outpatient surgical centers—in short, it's a business model built on efficiencies. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches.
read more >

More Expert Comments

Experts Following This Company

Sheila Broughton, Analyst – PI Financial
Bruce Campbell, Founder and Portfolio Manager – Stonecastle Investment Management
Charles Haff – Craig-Hallum Capital
Russell Stanley, VP and Special Situations Analyst – Mackie Research Capital
James West, Publisher and Editor Midas Letter

The information provided above is from analysts, newsletters, the company and other contributors.

Nobilis Health Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Under-leveraged versus peers, allowing for M&A activity in 2016
 
2016 Guidance of $320 million in revenue, $65 million ADJ EBITDA
 
$42.1 million in Adj. EBITDA for the full year 2015, an increase $31.0 million over the full year of 2014
 
$229.2 million in total revenues for the full year 2015, an increase of $145.2 million over the full year of 2014